Anxiolytic Mechanisms
The neurobiology of anxiety and how benzodiazepines, buspirone, SSRIs, and emerging agents reduce pathological anxiety.
## Neurobiology of Anxiety
Anxiety involves hyperactivity of the amygdala fear circuit, excessive noradrenergic tone from the locus coeruleus, and insufficient GABAergic and serotonergic inhibition. The HPA axis (CRF -> ACTH -> cortisol) is chronically activated in anxiety disorders, contributing to physiological stress responses.
## Benzodiazepines
Benzodiazepines (diazepam, lorazepam, alprazolam, clonazepam) bind the alpha/gamma interface of GABA-A receptors, increasing chloride channel opening frequency. Effects are rapid (minutes to hours), providing acute relief.
**Limitations:**
- Tolerance and physical dependence develop with chronic use
- Withdrawal seizures with abrupt discontinuation
- Cognitive impairment, sedation, and fall risk in elderly
- Abuse potential, especially with short-acting agents (alprazolam)
- Flumazenil reverses benzodiazepine effects but can precipitate seizures in dependent patients
## Buspirone
Buspirone is a 5-HT1A partial agonist with anxiolytic properties. It has no sedation, no abuse potential, and no cross-tolerance with benzodiazepines. The 2-4 week onset delay limits its use for acute anxiety. It is effective for generalized anxiety disorder (GAD) but not panic disorder.
## SSRIs and SNRIs
SSRIs (escitalopram, sertraline) and SNRIs (venlafaxine, duloxetine) are first-line for most anxiety disorders including GAD, panic disorder, social anxiety, and PTSD. Their anxiolytic effect takes 2-6 weeks and involves serotonergic modulation of amygdala circuits. Initial paradoxical anxiety may occur in the first 1-2 weeks.
## Other Agents
- **Pregabalin** -- alpha-2-delta calcium channel ligand; approved for GAD in Europe; reduces excitatory neurotransmitter release
- **Hydroxyzine** -- H1 antihistamine; sedating anxiolytic for short-term use
- **Beta-blockers** -- propranolol blocks peripheral sympathetic symptoms (tremor, tachycardia) in performance anxiety; no central anxiolytic effect
- **Gabapentin** -- off-label for social anxiety; similar mechanism to pregabalin
## Emerging Targets
GABA-A positive allosteric modulators selective for alpha-2/3 subunits aim to provide anxiolysis without alpha-1-mediated sedation. CRF1 receptor antagonists and glutamate modulators are in development.
## Key Takeaways
- SSRIs/SNRIs are first-line for chronic anxiety disorders despite delayed onset
- Benzodiazepines provide rapid relief but carry dependence and cognitive risks
- Buspirone is a non-sedating alternative for GAD with no abuse potential
- Subtype-selective GABA-A modulators may offer anxiolysis without sedation